AG真人官方

STOCK TITAN

Prothena to Report Second Quarter 2025 Financial Results on August 4

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

DUBLIN--(BUSINESS WIRE)-- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2025 financial results on Monday, August 4, 2025, after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 4.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena鈥檚 pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including ATTR amyloidosis with cardiomyopathy, Alzheimer鈥檚 disease, Parkinson鈥檚 disease and a number of other neurodegenerative diseases. For more information, please visit the Company鈥檚 website at and follow the Company on X (formerly Twitter) @ProthenaCorp.

Mark Johnson, CFA, Vice President, Investor Relations

650-417-1974, [email protected]

Source: Prothena Corporation plc

Prothena

NASDAQ:PRTA

PRTA Rankings

PRTA Latest News

PRTA Latest SEC Filings

PRTA Stock Data

426.33M
42.97M
19.58%
74.3%
8.84%
Biotechnology
Pharmaceutical Preparations
Ireland
DUBLIN 2